HOXB8

Summary

HOXB8 (homeobox B8, HGNC:5119) is a protein-coding gene on chromosome 17q21.32, encoding Homeobox protein Hox-B8 (P17481). Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.

This gene is a member of the Antp homeobox family and encodes a nuclear protein with a homeobox DNA-binding domain. It is included in a cluster of homeobox B genes located on chromosome 17. The encoded protein functions as a sequence-specific transcription factor that is involved in development. Increased expression of this gene is associated with colorectal cancer. Mice that have had the murine ortholog of this gene knocked out exhibit an excessive pathologic grooming behavior. This behavior is similar to the behavior of humans suffering from the obsessive-compulsive spectrum disorder trichotillomania.

Source: NCBI Gene 3218 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 27 total
• MANE Select transcript: NM_024016

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5119
Approved symbol	HOXB8
Name	homeobox B8
Location	17q21.32
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000120068
Ensembl biotype	protein_coding
OMIM	142963
Entrez	3218

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000239144, ENST00000498634, ENST00000576562, ENST00000884865, ENST00000884866

RefSeq mRNA: 1 — MANE Select: NM_024016 NM_024016

CCDS: CCDS11533

Canonical transcript exons

ENST00000239144 — 2 exons

Exon	Start	End
ENSE00000812642	48614281	48615292
ENSE00001313788	48612346	48613509

Expression profiles

Bgee: expression breadth ubiquitous, 121 present calls, max score 88.56.

FANTOM5 (CAGE): breadth broad, TPM avg 3.5066 / max 195.4430, expressed in 650 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166717	1.1269	408
166724	0.6494	152
166727	0.3965	135
166719	0.3738	239
166723	0.3306	145
166722	0.1865	65
166726	0.1837	74
166721	0.1003	28
166720	0.0672	26
166718	0.0479	25

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	88.56	gold quality
metanephros cortex	UBERON:0010533	88.14	gold quality
seminal vesicle	UBERON:0000998	88.02	gold quality
kidney epithelium	UBERON:0004819	85.48	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	84.44	gold quality
spinal cord	UBERON:0002240	83.23	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.83	gold quality
adult mammalian kidney	UBERON:0000082	80.20	gold quality
ileal mucosa	UBERON:0000331	78.10	gold quality
mucosa of transverse colon	UBERON:0004991	77.11	gold quality
metanephros	UBERON:0000081	75.81	gold quality
right adrenal gland	UBERON:0001233	75.48	gold quality
caput epididymis	UBERON:0004358	75.07	gold quality
small intestine Peyer’s patch	UBERON:0003454	74.35	gold quality
left adrenal gland cortex	UBERON:0035825	73.98	gold quality
oviduct epithelium	UBERON:0004804	73.63	gold quality
left adrenal gland	UBERON:0001234	73.59	gold quality
omental fat pad	UBERON:0010414	73.33	gold quality
cortex of kidney	UBERON:0001225	73.31	gold quality
peritoneum	UBERON:0002358	73.24	gold quality
right adrenal gland cortex	UBERON:0035827	73.16	gold quality
kidney	UBERON:0002113	72.29	gold quality
adipose tissue of abdominal region	UBERON:0007808	72.04	gold quality
transverse colon	UBERON:0001157	71.50	gold quality
adrenal cortex	UBERON:0001235	71.48	gold quality
colonic epithelium	UBERON:0000397	70.93	gold quality
small intestine	UBERON:0002108	69.11	gold quality
adrenal gland	UBERON:0002369	69.11	gold quality
endometrium	UBERON:0001295	67.68	gold quality
cauda epididymis	UBERON:0004360	67.56	silver quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-56	yes	1029.31
E-ANND-3	no	2.30

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

4 targets.

Target	Regulation
ACTA2	Repression
EIF3K
MYLK	Repression
TAGLN	Repression

JASPAR motifs

Motif	Name	Family
MA1502.1	HOXB8	HOX
MA1502.2	HOXB8	HOX

JASPAR matrix evidence (PMIDs): PMID:18585359

Upstream regulators (CollecTRI, top): ARID4B, HOXC10, HOXC9

miRNA regulators (miRDB)

67 targeting HOXB8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-449C-5P	99.78	67.63	1168

Literature-anchored findings (GeneRIF, showing 14)

• HOXB5 and HOXB8 are frequently expressed in ovarian serous carcinoma, with anatomic site-related differences for cytoplasmic staining. HOXB8 expression is associated with shorter survival in metastatic serous carcinoma. (PMID:23438671)
• HOXB8 and KLK11 may be classified as valuable biomarkers, as they can predict the effects of FOLFOX4 chemotherapy in primary advanced colorectal cancer patients (PMID:23647300)
• Results show that FMRP regulates miR196a-mediated repression of HOXB8 via interaction with the AGO2 MID domain. (PMID:24727796)
• Knockdown of ZEB2 can inhibit HOXB8-induced migration and invasion capacity, as well as the epithelial-mesenchymal transformation in gastric cancer cells. The results showed that HOXB8 plays an important role in the development and metastasis of gastric carcinoma (PMID:27761656)
• miR-32-5p significantly downregulated in cervical cancer (CCa) tissues and cells. Bioinformatics and Luciferase method screened HOXB8 as a downstream regulatory target of miR-32-5p. Besides, HOXB8 was incredibly highly expressed in CCa tissues and cells. Decreased expression of HOXB8 resulting from upregulation of miR-32-5p could weaken cell proliferation, clone formation, invasion and migration ability of HeLa cells. (PMID:30657550)
• HOXB8 knockdown inhibited cell proliferation. The invasiveness of HCT116 cells was significantly reduced following HOXB8 depletion compared with that in the shRNA control group, whereby the rates were reduced by 67% in HOXB8 knockdown group. (PMID:30677006)
• knockdown of HOXB8 could suppress tumorigenesis and metastasis in OS through regulation of the Wnt/beta-catenin signaling pathway (PMID:30954562)
• Knockdown of HOXB8 abolished the effects of miR-128 inhibitor on ovarian cancer cell proliferation and paclitaxel sensitivity. Summarily, miR-128 displayed a tumour suppressor role in ovarian cancer via targeting HOXB8. (PMID:31271703)
• Oncogenic HOXB8 is driven by MYC-regulated super-enhancer and potentiates colorectal cancer invasiveness via BACH1. (PMID:31591481)
• Homeobox B8 Targets Sterile Alpha Motif Domain-Containing Protein 9 and Drives Glioma Progression. (PMID:31646435)
• SNHG3/miR-2682-5p/HOXB8 promotes cell proliferation and migration in oral squamous cell carcinoma. (PMID:32989886)
• LINC01116 boosts the progression of pituitary adenoma via regulating miR-744-5p/HOXB8 pathway. (PMID:34098015)
• Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. (PMID:34432948)
• HOXB8 Counteracts MAPK/ERK Oncogenic Signaling in a Chicken Embryo Model of Neoplasia. (PMID:34445617)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	hoxb8b	ENSDARG00000054025
danio_rerio	hoxb8a	ENSDARG00000056027
mus_musculus	Hoxb8	ENSMUSG00000056648
rattus_norvegicus	Hoxb8	ENSRNOG00000007585

Paralogs (42): HOXA11 (ENSG00000005073), HOXC8 (ENSG00000037965), HOXA1 (ENSG00000105991), HOXA2 (ENSG00000105996), HOXA3 (ENSG00000105997), HOXA5 (ENSG00000106004), HOXA6 (ENSG00000106006), HOXA13 (ENSG00000106031), TLX1 (ENSG00000107807), HOXB6 (ENSG00000108511), TLX2 (ENSG00000115297), HOXB5 (ENSG00000120075), HOXB3 (ENSG00000120093), HOXB1 (ENSG00000120094), HOXA7 (ENSG00000122592), HOXC13 (ENSG00000123364), HOXC11 (ENSG00000123388), HOXC12 (ENSG00000123407), HOXD1 (ENSG00000128645), HOXD3 (ENSG00000128652), HOXD9 (ENSG00000128709), HOXD10 (ENSG00000128710), HOXD11 (ENSG00000128713), HOXD13 (ENSG00000128714), PDX1 (ENSG00000139515), HOXB13 (ENSG00000159184), TLX3 (ENSG00000164438), HOXD4 (ENSG00000170166), HOXD12 (ENSG00000170178), HOXB9 (ENSG00000170689), HOXC5 (ENSG00000172789), HOXB2 (ENSG00000173917), HOXD8 (ENSG00000175879), GSX2 (ENSG00000180613), HOXC9 (ENSG00000180806), HOXC10 (ENSG00000180818), HOXB4 (ENSG00000182742), HOXA4 (ENSG00000197576), HOXC6 (ENSG00000197757), HOXC4 (ENSG00000198353)

Protein

Protein identifiers

Homeobox protein Hox-B8 — P17481 (reviewed: P17481)

Alternative names: Homeobox protein Hox-2.4, Homeobox protein Hox-2D

All UniProt accessions (3): P17481, I3L383, I3L3R1

UniProt curated annotations — full annotation on UniProt →

Function. Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.

Subunit / interactions. Forms a DNA-binding heterodimer with transcription factor PBX1.

Subcellular location. Nucleus.

Similarity. Belongs to the Antp homeobox family.

RefSeq proteins (1): NP_076921* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000047	HTH_motif	Conserved_site
IPR001356	HD	Domain
IPR001827	Homeobox_Antennapedia_CS	Conserved_site
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR017970	Homeobox_CS	Conserved_site
IPR020479	HD_metazoa	Domain
IPR050948	Antp_homeobox_TF	Family

Pfam: PF00046

UniProt features (4 total): chain 1, DNA-binding region 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P17481-F1	65.31	0.27

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 199 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_SPINAL_CORD_DEVELOPMENT, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, YAATNRNNNYNATT_UNKNOWN, BENPORATH_ES_WITH_H3K27ME3, HNF3ALPHA_Q6, GOBP_BEHAVIOR, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT, CMYB_01, GOBP_ADULT_BEHAVIOR, SP3_Q3, GOBP_EMBRYONIC_SKELETAL_SYSTEM_MORPHOGENESIS, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP

GO Biological Process (11): regulation of transcription by RNA polymerase II (GO:0006357), grooming behavior (GO:0007625), adult locomotory behavior (GO:0008344), anterior/posterior pattern specification (GO:0009952), sensory perception of pain (GO:0019233), dorsal spinal cord development (GO:0021516), negative regulation of myeloid cell differentiation (GO:0045638), embryonic skeletal system morphogenesis (GO:0048704), negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), skeletal system morphogenesis (GO:0048705)

GO Molecular Function (7): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
transcription cis-regulatory region binding	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular anatomical structure	2
behavior	1
locomotory behavior	1
adult behavior	1
regionalization	1
sensory perception	1
spinal cord development	1
anatomical structure development	1
myeloid cell differentiation	1
negative regulation of cell differentiation	1
regulation of myeloid cell differentiation	1
embryonic organ morphogenesis	1
skeletal system morphogenesis	1
embryonic skeletal system development	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
skeletal system development	1
animal organ morphogenesis	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
transcription regulator activity	1
DNA binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1

Protein interactions and networks

STRING

1000 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HOXB8	DLGAP3	O95886	801
HOXB8	PBX1	P40424	780
HOXB8	MEIS1	O00470	603
HOXB8	IRX2	Q9BZI1	576
HOXB8	SLITRK5	O94991	573
HOXB8	MEIS2	O14770	552
HOXB8	DICER1	Q9UPY3	533
HOXB8	SHH	Q15465	516
HOXB8	GATA4	P43694	442
HOXB8	ISL1	P20663	435
HOXB8	PRSS58	Q8IYP2	420
HOXB8	BNC2	Q6ZN30	410
HOXB8	HOXC9	P31274	389
HOXB8	PAX1	P15863	387
HOXB8	CDH7	Q9ULB5	386

IntAct

3 interactions, top by confidence:

A	B	Type	Score
FAM110D	NDUFA2	psi-mi:“MI:0914”(association)	0.350
HOXB8	IMPDH1	psi-mi:“MI:0914”(association)	0.350

BioGRID (18): PBX3 (Reconstituted Complex), PBX1 (Reconstituted Complex), BACH1 (Co-localization), BACH1 (Affinity Capture-Western), HOXB8 (Affinity Capture-Western), FBXO7 (Affinity Capture-MS), KCTD9 (Affinity Capture-MS), MMADHC (Affinity Capture-MS), ANKHD1-EIF4EBP3 (Affinity Capture-MS), TBC1D23 (Affinity Capture-MS), HOXB8 (Affinity Capture-MS), PSMF1 (Affinity Capture-MS), IMPDH1 (Affinity Capture-MS), GKN2 (Affinity Capture-MS), LONP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1W2PPK0, A0A1W2PPM1, A1YFT7, A2D5V0, A2T7D1, A7Y7W3, A9L937, B0VXK3, F1Q4R9, G3X9P6, G3X9U1, O43364, P09025, P09092, P09632, P17278, P17481, P24342, P28358, P28359, P31245, P31246, P31263, P31273, Q0VCS4, Q1ECY2, Q1KKS8, Q1KKT2, Q1KKV1, Q1KKV4, Q1KKZ4, Q1KKZ6, Q3LTE0, Q3UT54, Q4JM65, Q4KL20, Q5TM83, Q5TM84, Q68EH7, Q6JIY4

Diamond homologs: A1YFA5, A1YFD8, A1YGK7, A2D5K9, A2D5Y4, A2T7F3, B0W1V2, O42504, P02830, P02832, P02833, P04476, P09013, P09014, P09016, P09017, P09019, P09020, P09021, P09023, P09024, P09025, P09067, P09071, P09074, P09077, P09079, P09080, P09092, P09629, P09630, P09632, P09634, P09636, P09637, P10284, P10629, P14838, P14839, P14840

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
HOXB8	“up-regulates activity”	PBX3	binding
HOXB8	“up-regulates activity”	PBX1	binding
HOXB8	“down-regulates quantity by repression”	MYLK	“transcriptional regulation”
HOXB8	“down-regulates quantity by repression”	ACTA2	“transcriptional regulation”
HOXB8	“down-regulates quantity by repression”	TAGLN	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	26
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

245 predictions. Top by Δscore:

Variant	Effect	Δscore
17:48614276:CTCA:C	donor_loss	1.0000
17:48614277:TCAC:T	donor_loss	1.0000
17:48614278:CA:C	donor_loss	1.0000
17:48614279:A:AG	donor_loss	1.0000
17:48614280:C:CA	donor_loss	1.0000
17:48613507:CTG:C	acceptor_gain	0.9900
17:48613510:C:CC	acceptor_gain	0.9900
17:48613516:A:AC	acceptor_gain	0.9900
17:48614279:A:AC	donor_gain	0.9900
17:48614280:C:CC	donor_gain	0.9900
17:48614280:CCTTG:C	donor_gain	0.9900
17:48613504:CGG:C	acceptor_gain	0.9800
17:48613505:GGCTG:G	acceptor_gain	0.9800
17:48613508:TG:T	acceptor_gain	0.9800
17:48614275:GCTCA:G	donor_loss	0.9800
17:48613505:GGC:G	acceptor_loss	0.9700
17:48613506:GC:G	acceptor_loss	0.9700
17:48613507:C:A	acceptor_loss	0.9700
17:48613508:T:G	acceptor_loss	0.9700
17:48613503:GCGG:G	acceptor_gain	0.9600
17:48613504:CGGC:C	acceptor_gain	0.9600
17:48613506:GCTGC:G	acceptor_gain	0.9600
17:48613507:CTGCT:C	acceptor_gain	0.9600
17:48613516:A:C	acceptor_gain	0.9600
17:48613502:GGCGG:G	acceptor_gain	0.9500
17:48613506:GCTG:G	acceptor_loss	0.9500
17:48613507:CTGC:C	acceptor_loss	0.9500
17:48613509:GC:G	acceptor_loss	0.9500
17:48613510:C:A	acceptor_loss	0.9500
17:48613511:T:C	acceptor_loss	0.9500

AlphaMissense

1581 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:48613325:T:A	K203N	1.000
17:48613325:T:G	K203N	1.000
17:48613326:T:A	K203I	1.000
17:48613327:T:C	K203E	1.000
17:48613328:T:A	K202N	1.000
17:48613328:T:G	K202N	1.000
17:48613329:T:A	K202I	1.000
17:48613330:T:C	K202E	1.000
17:48613333:A:G	W201R	1.000
17:48613333:A:T	W201R	1.000
17:48613334:C:A	K200N	1.000
17:48613334:C:G	K200N	1.000
17:48613335:T:A	K200M	1.000
17:48613336:T:C	K200E	1.000
17:48613337:C:A	M199I	1.000
17:48613337:C:G	M199I	1.000
17:48613337:C:T	M199I	1.000
17:48613338:A:C	M199R	1.000
17:48613338:A:G	M199T	1.000
17:48613338:A:T	M199K	1.000
17:48613340:C:A	R198S	1.000
17:48613340:C:G	R198S	1.000
17:48613341:C:A	R198M	1.000
17:48613341:C:G	R198T	1.000
17:48613342:T:A	R198W	1.000
17:48613342:T:C	R198G	1.000
17:48613344:C:A	R197L	1.000
17:48613344:C:G	R197P	1.000
17:48613345:G:A	R197W	1.000
17:48613345:G:C	R197G	1.000

dbSNP variants (sampled 300 via entrez): RS1000072656 (17:48612023 T>C), RS1001957463 (17:48612851 A>G), RS1002748353 (17:48613657 G>GA), RS1002823054 (17:48614866 AAAAGAAAAG>A), RS1003942953 (17:48612616 G>C), RS1004033774 (17:48615603 C>T), RS1005715081 (17:48614177 G>C,T), RS1006154204 (17:48617250 C>A,T), RS1006230167 (17:48615894 T>G), RS1006929076 (17:48613902 T>A), RS1007657344 (17:48616906 T>A), RS1008017618 (17:48614986 G>A,C), RS1008293966 (17:48614056 G>T), RS1008320816 (17:48613745 C>G,T), RS1009073900 (17:48615245 G>A,T)

Disease associations

OMIM: gene MIM:142963 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	2
Tretinoin	increases expression	2
3,19-(2-bromobenzylidene)andrographolide	decreases response to substance, increases expression	1
beta-lapachone	decreases expression	1
arsenite	increases methylation	1
ferrous chloride	decreases expression	1
abrine	decreases expression	1
(+)-JQ1 compound	increases expression	1
EPZ004777	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Arbutin	decreases expression	1
Cytarabine	decreases expression	1
Methotrexate	decreases expression	1
Triclosan	increases expression	1
Tunicamycin	decreases expression	1
Valproic Acid	affects expression	1
Aflatoxin B1	decreases methylation	1
Asbestos, Crocidolite	decreases methylation	1
Asbestos, Amosite	decreases methylation	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.